Influence of radiotherapy interruption on esophageal cancer with intensity-modulated radiotherapy: a retrospective study.
Humans
Esophageal Neoplasms
/ radiotherapy
Retrospective Studies
Male
Female
Middle Aged
Radiotherapy, Intensity-Modulated
/ methods
Aged
Chemoradiotherapy
/ methods
Esophageal Squamous Cell Carcinoma
/ radiotherapy
Adult
Prognosis
Neoplasm Recurrence, Local
/ prevention & control
Survival Rate
Kaplan-Meier Estimate
Aged, 80 and over
Proportional Hazards Models
Delayed time
Esophageal cancer
Radiotherapy
Radiotherapy interruption
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
27 May 2024
27 May 2024
Historique:
received:
21
12
2023
accepted:
14
05
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
27
5
2024
Statut:
epublish
Résumé
Radiotherapy interruption (RTI) prolongs the overall total treatment time and leads to local control loss in many cancers, but it is unclear in esophageal cancer. We aimed to evaluate the influence of RTI on the overall survival (OS), progression-free survival (PFS), and local-regional recurrence-free survival (LRFS) of patients with esophageal cancer undergoing chemoradiotherapy. A total of 299 patients with esophageal squamous cell carcinoma from 2017 to 2019 were retrospectively analyzed to investigate the effect of RTI on OS, PFS, and LRFS. The delayed time of radiotherapy interruption was calculated as the actual radiation treatment time minus the scheduled time. The univariate and multivariate analyses were performed by the COX proportional hazards regression models, and the survival analysis was performed through the Kaplan‒Meier method, and compared with the log-rank test. The 3-year OS, PFS, and LRFS rates were 53.0%, 42.0%, and 48.0%, respectively. The univariate and multivariate analyses showed that the delayed time > 3 days was an independent adverse prognostic factor for OS (HR = 1.68, 95% CI 1.10-2.55, p = 0.016), and LRFS (HR = 1.74, 95% CI 1.18-2.57, p = 0.006). The patient with a delayed time of > 3 days had poorer survival rates of OS, and LRFS than patients with a delayed time of ≤ 3 days (OS, p = 0.047; LRFS, p = 0.013), and the survival outcomes of patients with shorter delayed time (1-3 days) were slightly different from the patients without interruptions. The impact of delay time on PFS is not statistically significant, but the survival outcomes of the two groups were slightly different. There was a significant correlation between delayed time and local control of esophageal cancer. The delayed time for more than 3 days might decrease the survival outcome, and increase the local recurrence risk.
Sections du résumé
BACKGROUND
BACKGROUND
Radiotherapy interruption (RTI) prolongs the overall total treatment time and leads to local control loss in many cancers, but it is unclear in esophageal cancer. We aimed to evaluate the influence of RTI on the overall survival (OS), progression-free survival (PFS), and local-regional recurrence-free survival (LRFS) of patients with esophageal cancer undergoing chemoradiotherapy.
METHODS
METHODS
A total of 299 patients with esophageal squamous cell carcinoma from 2017 to 2019 were retrospectively analyzed to investigate the effect of RTI on OS, PFS, and LRFS. The delayed time of radiotherapy interruption was calculated as the actual radiation treatment time minus the scheduled time. The univariate and multivariate analyses were performed by the COX proportional hazards regression models, and the survival analysis was performed through the Kaplan‒Meier method, and compared with the log-rank test.
RESULTS
RESULTS
The 3-year OS, PFS, and LRFS rates were 53.0%, 42.0%, and 48.0%, respectively. The univariate and multivariate analyses showed that the delayed time > 3 days was an independent adverse prognostic factor for OS (HR = 1.68, 95% CI 1.10-2.55, p = 0.016), and LRFS (HR = 1.74, 95% CI 1.18-2.57, p = 0.006). The patient with a delayed time of > 3 days had poorer survival rates of OS, and LRFS than patients with a delayed time of ≤ 3 days (OS, p = 0.047; LRFS, p = 0.013), and the survival outcomes of patients with shorter delayed time (1-3 days) were slightly different from the patients without interruptions. The impact of delay time on PFS is not statistically significant, but the survival outcomes of the two groups were slightly different.
CONCLUSION
CONCLUSIONS
There was a significant correlation between delayed time and local control of esophageal cancer. The delayed time for more than 3 days might decrease the survival outcome, and increase the local recurrence risk.
Identifiants
pubmed: 38802765
doi: 10.1186/s12885-024-12383-7
pii: 10.1186/s12885-024-12383-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
646Informations de copyright
© 2024. The Author(s).
Références
Hulshof MCCM, Geijsen ED, Rozema T et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol. 2021-09-01;39(25):2816–24. https://doi.org/10.1200/JCO.20.03697 .
Sugawara K, Yamashita H, Okumura Y, et al. Age-dependent survival impact of body mass index in patients with oesophageal squamous cell carcinoma. EJSO-Eur J Surg Onc. 2020-10-01;46(10 Pt A):1948–55. https://doi.org/10.1016/j.ejso.2020.05.012 .
Spreafico A, Coate L, Zhai R, et al. Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. Cancer Epidemiol. 2017;47:28–34. https://doi.org/10.1016/j.canep.2016.11.009 .
doi: 10.1016/j.canep.2016.11.009
pubmed: 28088657
Wang R, Zhou XM, Liu TX et al. Gross tumor volume predicts survival and pathological complete response of locally Advanced Esophageal Cancer after Neoadjuvant Chemoradiotherapy. Front Oncol. 2022-01-01;12:898383. https://doi.org/10.3389/fonc.2022.898383 .
Huang X, Jiang DX,Jian ZT et al. Identification of optimal parameters for assessing Lymph Node Status of patients with esophageal squamous cell Carcinoma after Neoadjuvant Chemoradiotherapy. Ann Surg Oncol. 2023 https://doi.org/10.1245/s10434-023-14135-6 .
Cheng X, Yang KB, Feng RJ et al. Radiotherapy interruption due to holidays adversely affects the survival of patients with nasopharyngeal carcinoma: a joint analysis based on large-scale retrospective data and clinical trials. Radiat Oncol. 2022-02-19;17(1):36. https://doi.org/10.1186/s13014-022-02006-5 .
Yeh SA, Hwang TZ, Wang CC, Yang CC, Lien CF, Wang CC, et al. Outcomes of patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. J Radiat Res. 2021;62:438–47. https://doi.org/10.1093/jrr/rrab008 .
doi: 10.1093/jrr/rrab008
pubmed: 33783535
pmcid: 8127674
Barton MB, Keane TJ, Gadalla T et al. The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. Radiother Oncol. 1992-03-01;23(3):137 – 43. https://doi.org/10.1016/0167-8140(92)90323-m .
Chen CM, Kong LZ. The guidelines of the Prevention and Control of overweight and obesity in Chinese Adults[M]. Beijing: People’s Medical Publishing House; 2006. p. 3.
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
doi: 10.3322/caac.21338
pubmed: 26808342
Xin Z, Liu Q, Ai D et al. Radiotherapy for Advanced Esophageal Cancer: from Palliation to Curation. Curr Treat Option On. 2023-11-01;24(11):1568–79. https://doi.org/10.1007/s11864-023-01134-8 .
Kim K, Oh D, Noh JM, et al. Outcomes following hypofractionated radiation therapy alone for surgically unfit early esophageal squamous cell carcinoma patients; a retrospective single center analysis. Radiother Oncol. 2023. https://doi.org/10.1016/j.radonc.2023.109982 .
doi: 10.1016/j.radonc.2023.109982
pubmed: 38142936
Yarn C, Wakefield DV, Spencer S et al. Insurance status and head and neck radiotherapy interruption disparities in the Mid-southern United States. Head Neck-J Sci Spec. 2020-08-01;42(8):2013–20. https://doi.org/10.1002/hed.26128 .
Zhao FR, Yang DSi, Li XP. Effect of radiotherapy interruption on nasopharyngeal cancer. Front Oncol. 2023. https://doi.org/10.3389/fonc.2023.1114652 .
doi: 10.3389/fonc.2023.1114652
pubmed: 38352299
pmcid: 10795173
Pechačová Z, Lohynská R. Clinical application of time factor principles in radiotherapy in compensation of radiation series interruptions. Klin Onkol. 2021-01-01;34(6):455–62. https://doi.org/10.48095/ccko2021455 .
Nishimura Y, Ono K, Tsutsui K et al. Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation. Int J Radiat Oncol. 1994-12-01;30(5):1099 – 105. https://doi.org/10.1016/0360-3016(94)90315-8 .
Yao JJ, Zhang FG, Tian S, et al. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Radiother Oncol. 2019-03-01;132:178–87. https://doi.org/10.1016/j.radonc.2018.10.018 .
Yao JJ, Jin YN, Wang SY et al. The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis. BMC cancer.2018;18 (1):740. https://doi.org/10.1186/s12885-018-4495-2 .
Withers H R, Taylor J M, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27(2):131–46. https://doi.org/10.3109/02841868809090333 .
Dale RG, Jones B. Radiotherapy treatment interruptions during the Covid-19 pandemic: the UK experience and implications for radiobiology training. Radiat Phys Chem. 2022-11-01; https://doi.org/10.1016/j.radphyschem.2022.110214 .
Xu GZ, Li L, Zhu XD. Effect of interrupted time during intensity modulated radiation therapy on survival outcomes in patients with nasopharyngeal cancer.Oncotarget.2017;8 (23): 37817–25. https://doi.org/10.18632/oncotarget.13713 .
Hallemeier CL, Moughan J, Haddock MG, et al. Association of Radiotherapy Duration with Clinical outcomes in patients with esophageal Cancer treated in NRG oncology trials: a secondary analysis of NRG Oncology Randomized clinical trials. JAMA Netw Open. 2023;6(4):e238504. https://doi.org/10.1001/jamanetworkopen.2023.8504 .
doi: 10.1001/jamanetworkopen.2023.8504
pubmed: 37083668
pmcid: 10122174
Skladowski K, Law MG, Maciejewski B, et al. Planned and unplanned gaps in radiotherapy: the importance of gap position and gap duration. Radiother Oncol. 1994;2109–20. https://doi.org/10.1016/0167-8140(94)90039-6 . -02-01;30.
Razmjoo S, Haghi N, Birgani MJT, et al. Radiotherapy Interruption in Cancer patients: Rates and causes at Ahvaz Golestan Hospital.Asian Pacific. J Cancer Care. 2020;110.31557/APJCC.2020.5.1.33-36.
Sapienza Lucas G, Raychaudhuri S, Nahlawi Suraya K et al. Predictors of definitive treatment interruptions of Long-Course Neoadjuvant Chemoradiotherapy in locally advanced rectal Cancer. Cureus. 2022-10-01;14(10):e30159. https://doi.org/10.7759/cureus.30159 .
Zhou SX, Yang Y, Zhang Q et al. Analysis of the prognostic factors of simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT) in 220 cases of locally advanced squamous esophageal cancer: a retrospective cohort study. Ann Transl Med. 2023-01-31;11(2):103. https://doi.org/10.21037/atm-22-6462 .
Yuan S, Wei C,Wang M, et al. Prognostic impact of examined lymph-node count for patients with esophageal cancer: development and validation prediction model. Sci Rep. 2023;13(1):476. https://doi.org/10.1038/s41598-022-27150-6 .
doi: 10.1038/s41598-022-27150-6
pubmed: 36627338
pmcid: 9831985
Chen J, Lin Y, Cai W et al. A new clinical staging system for esophageal cancer to predict survival after definitive chemoradiation or radiotherapy. Dis Esophagus. 2018-11-01;31(11). https://doi.org/10.1093/dote/doy043 .